BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26

Reuters

Oct 02

Oct 1 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLUTION OF DISPUTES WITH THE U.S. FOOD AND DRUG ADMINISTRATION
VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF TRADIPITANT BY NOV 26, 2025
VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF HETLIOZ SNDA BY JAN 7, 2026
VANDA PHARMACEUTICALS INC - FDA AND VANDA TO SEEK PAUSE OF TRADIPITANT NDA PROCEEDINGS UNTIL JAN 7, 2026
VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT ON HETLIOZ EFFICACY INFORMATION
VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT CHALLENGING FDA'S CLINICAL HOLD ON TRADIPITANT

Source text: ID:nPn7P77B0a

Further company coverage: VNDA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572568363"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572568363\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572568363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572568363","market":"us","top_or_hot":-1,"title":"BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26</title></head><body><p><span>Oct 1 (Reuters)</span><span> - </span>Vanda Pharmaceuticals Inc <span>VNDA.O</span>:</p><ul><li><p>VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLUTION OF DISPUTES WITH THE U.S. FOOD AND DRUG ADMINISTRATION</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF TRADIPITANT BY NOV 26, 2025</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF HETLIOZ SNDA BY JAN 7, 2026</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA AND VANDA TO SEEK PAUSE OF TRADIPITANT NDA PROCEEDINGS UNTIL JAN 7, 2026</p></li><li><p>VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT ON HETLIOZ EFFICACY INFORMATION</p></li><li><p>VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT CHALLENGING FDA'S CLINICAL HOLD ON TRADIPITANT</p></li></ul><p>Source text: <span>ID:nPn7P77B0a</span></p><p>Further company coverage: <span>VNDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26</title></head><body><p><span>Oct 1 (Reuters)</span><span> - </span>Vanda Pharmaceuticals Inc <span>VNDA.O</span>:</p><ul><li><p>VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLUTION OF DISPUTES WITH THE U.S. FOOD AND DRUG ADMINISTRATION</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF TRADIPITANT BY NOV 26, 2025</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF HETLIOZ SNDA BY JAN 7, 2026</p></li><li><p>VANDA PHARMACEUTICALS INC - FDA AND VANDA TO SEEK PAUSE OF TRADIPITANT NDA PROCEEDINGS UNTIL JAN 7, 2026</p></li><li><p>VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT ON HETLIOZ EFFICACY INFORMATION</p></li><li><p>VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT CHALLENGING FDA'S CLINICAL HOLD ON TRADIPITANT</p></li></ul><p>Source text: <span>ID:nPn7P77B0a</span></p><p>Further company coverage: <span>VNDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nTUA8LLD4B:1","article_id":"2572568363","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572568363","pubTimestamp":1759352949,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26Oct 1 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VNDA":"万达生物制药"},"translate_title":"简介-Vanda Pharmaceuticals表示FDA将在11月26日之前加快对Tradipitant的重新审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNDA":0.9},"content_text":"BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26Oct 1 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLUTION OF DISPUTES WITH THE U.S. FOOD AND DRUG ADMINISTRATIONVANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF TRADIPITANT BY NOV 26, 2025VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF HETLIOZ SNDA BY JAN 7, 2026VANDA PHARMACEUTICALS INC - FDA AND VANDA TO SEEK PAUSE OF TRADIPITANT NDA PROCEEDINGS UNTIL JAN 7, 2026VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT ON HETLIOZ EFFICACY INFORMATIONVANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT CHALLENGING FDA'S CLINICAL HOLD ON TRADIPITANTSource text: ID:nPn7P77B0aFurther company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}